RAAS & Volume Regulation — RAAS and volume regulation connections - Pathophysiology

SECTION 1

Historical Context & Motivation

The quest to understand how the body maintains a stable circulating volume and blood pressure stretches back more than a century. Early physiologists recognized that the kidney was far more than a simple filter; it was an endocrine organ capable of releasing substances that profoundly influenced the cardiovascular system. The discovery of renin by Robert Tigerstedt and Per Bergman in 1898 opened a line of inquiry that would ultimately reveal the renin-angiotensin-aldosterone system (RAAS) — a hormonal cascade that integrates renal, adrenal, hepatic, and pulmonary function to regulate extracellular fluid volume and systemic perfusion pressure. Understanding RAAS is essential for healthcare professionals because its dysregulation underlies hypertension, heart failure, chronic kidney disease, and numerous edematous states encountered daily in clinical practice.

1898 • Discovery of Renin

Tigerstedt and Bergman demonstrated that crude kidney extracts from rabbits caused a sustained rise in arterial pressure, and they named the responsible substance renin. This landmark finding established the kidney as an endocrine organ involved in blood pressure regulation.

1940 • Angiotensin Identified

Two independent groups — Braun-Menéndez in Argentina and Page & Helmer in the United States — isolated angiotensin (initially called 'angiotonin' and 'hypertensin'). They demonstrated that renin acted on a plasma substrate to generate a potent vasoconstrictor peptide.

1953 • Aldosterone Isolated

Simpson and Tait isolated aldosterone from the adrenal cortex, revealing the mineralocorticoid that linked angiotensin signaling to sodium retention and potassium excretion in the distal nephron.

1977 • ACE Inhibitors Enter Clinics

The development of captopril — the first orally active angiotensin-converting enzyme (ACE) inhibitor — validated RAAS as a therapeutic target and transformed the management of hypertension and heart failure.

1995–Present • ARBs, MRAs, and Beyond

Angiotensin-receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and the direct renin inhibitor aliskiren broadened the pharmacologic arsenal, while ongoing research into SGLT2 inhibitors and finerenone continues to refine volume-regulation strategies.

A central question unifies these discoveries: How does a single hormonal axis sense volume depletion, coordinate a multi-organ response, and then shut itself off once homeostasis is restored — and what happens when these feedback loops fail? Answering this question is the focus of the present lesson.

SECTION 2

Core Principles & Definitions

Before dissecting the cascade step by step, it is important to anchor several foundational principles that govern RAAS physiology and its connection to volume regulation. These concepts apply across virtually every clinical scenario in which fluid balance is disturbed.

Effective Circulating Volume (ECV)

The ECV refers to the portion of total body fluid that effectively perfuses tissues. It is a functional — not measurable — quantity. RAAS responds primarily to changes in ECV rather than total body water.

Juxtaglomerular Apparatus (JGA)

The JGA is a specialized structure where the distal tubule contacts its own afferent arteriole. It contains renin-secreting granular cells and macula densa cells that sense tubular NaCl delivery, forming the primary sensor of the RAAS cascade.

Angiotensinogen → Angiotensin II

Hepatic angiotensinogen is cleaved by renin to form angiotensin I, which is then converted to the biologically active angiotensin II (Ang II) by ACE in pulmonary and systemic vascular endothelium. Ang II is the principal effector hormone of the RAAS.

Aldosterone & Sodium Handling

Ang II stimulates the adrenal zona glomerulosa to secrete aldosterone, which upregulates epithelial sodium channels (ENaC) and Na⁺/K⁺-ATPase in the cortical collecting duct, promoting sodium reabsorption and potassium secretion.

Negative Feedback & Counter-Regulation

Volume repletion restores renal perfusion pressure and tubular NaCl delivery, suppressing renin release. Concurrently, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) oppose RAAS by promoting natriuresis and vasodilation.

✦

KEY TAKEAWAY

Think of RAAS as a thermostat for blood volume. When the 'temperature' (effective circulating volume) drops, the thermostat (JGA) activates the 'furnace' (angiotensin II and aldosterone), which 'heats' the system by retaining sodium and water and constricting vessels. Once the temperature reaches the set point, the thermostat clicks off. In diseases like heart failure, it is as though the thermostat sensor is miscalibrated — total body water may be high, yet the ECV 'reads' low, keeping the furnace running and producing pathological fluid retention.

SECTION 3

Visual Explanation — The RAAS Cascade

The RAAS cascade begins with decreased effective circulating volume (top, red border) sensed by the JGA, which releases renin. Sequential enzymatic steps produce angiotensin II, the central effector. Three major downstream arms — vasoconstriction, aldosterone-mediated sodium retention, and ADH-driven water reabsorption — collectively restore perfusion. Dashed lines represent the negative-feedback loop that suppresses renin once ECV normalizes.

The diagram above illustrates the hierarchical nature of the RAAS cascade: a single sensor mechanism at the JGA fans out into three complementary effector arms. Vasoconstriction elevates systemic vascular resistance (SVR) rapidly — within seconds — providing an acute hemodynamic response. Aldosterone-mediated sodium reabsorption acts over hours to days, expanding the extracellular fluid compartment. ADH (vasopressin), released from the posterior pituitary in response to both angiotensin II stimulation and elevated plasma osmolality, inserts aquaporin-2 channels in the collecting duct to retain free water. Together, these mechanisms restore effective circulating volume and close the feedback loop by increasing renal perfusion pressure and NaCl delivery to the macula densa, thereby suppressing further renin release.

SECTION 4

Mechanistic Deep Dive — Renin Secretion Triggers & Ang II Signaling

Three Triggers of Renin Release

Renin secretion from juxtaglomerular granular cells is governed by three convergent mechanisms that act as independent 'checks' on volume status. First, the intrarenal baroreceptor in the wall of the afferent arteriole senses a drop in transmural stretch when renal perfusion pressure falls below approximately 80 mmHg; reduced stretch directly stimulates renin exocytosis. Second, the macula densa mechanism detects decreased NaCl concentration in the tubular fluid at the thick ascending limb–distal convoluted tubule junction; reduced NaCl transport via the NKCC2 cotransporter triggers prostaglandin-mediated signaling that stimulates renin release. Third, sympathetic β₁-adrenergic stimulation from renal sympathetic nerves directly activates granular cell adenylyl cyclase, raising intracellular cAMP and promoting renin secretion. These three inputs are additive: hemorrhage activates all three simultaneously, producing maximal renin output.

Angiotensin II — Multi-Organ Effects

Angiotensin II exerts its effects through two principal receptor subtypes. The AT₁ receptor mediates vasoconstriction, aldosterone secretion, ADH release, sympathetic facilitation, proximal tubular Na⁺/H₂O reabsorption, and — crucially — cardiac and vascular remodeling through hypertrophic and pro-fibrotic signaling. The AT₂ receptor generally opposes AT₁ actions by promoting vasodilation, anti-proliferation, and natriuresis, though its physiological significance remains an area of active investigation. In the kidney, Ang II preferentially constricts the efferent arteriole, thereby raising glomerular filtration pressure and maintaining GFR even as renal plasma flow declines — a protective adaptation that becomes maladaptive in chronic kidney disease by perpetuating glomerular hypertension.

FILTRATION FRACTION

FF = GFR / RPF

FF = filtration fraction (normally ≈ 0.20); GFR = glomerular filtration rate; RPF = renal plasma flow. Ang II raises FF by constricting the efferent arteriole, which increases GFR relative to RPF. An elevated FF raises peritubular capillary oncotic pressure, enhancing proximal tubular sodium and water reabsorption.

MEAN ARTERIAL PRESSURE

MAP = CO × SVR

MAP = mean arterial pressure; CO = cardiac output; SVR = systemic vascular resistance. RAAS influences both variables: Ang II raises SVR via direct vasoconstriction, while aldosterone-mediated volume expansion increases venous return and thereby CO via the Frank-Starling mechanism.

💡

Clinical Note

ACE inhibitors and ARBs reduce efferent arteriolar tone, lowering glomerular capillary pressure and filtration fraction. This is why an initial dip in GFR of up to 30% is expected — and acceptable — after starting these medications in chronic kidney disease; it reflects a reduction in injurious glomerular hypertension rather than organ damage.

SECTION 5

Integrative Volume Regulation — RAAS, ANP, and ADH Cross-Talk

Volume regulation is not the province of RAAS alone; it emerges from the dynamic interplay between volume-retaining and volume-depleting neurohumoral systems. Understanding how these systems cross-talk is essential for deciphering pathological fluid states. The major counter-regulatory axis to RAAS is the natriuretic peptide system — consisting of ANP (released from atrial cardiomyocytes in response to stretch), BNP (released primarily from ventricular cardiomyocytes), and C-type natriuretic peptide (CNP, endothelial). These peptides activate guanylyl cyclase-linked receptors to promote renal sodium excretion, inhibit renin and aldosterone secretion, and cause vasodilation.

This diagram contrasts the two major neurohumoral axes governing volume: the volume-retaining RAAS axis (left) and the volume-depleting natriuretic peptide system (right). In health, these axes balance to maintain ECV homeostasis (center). In heart failure, the RAAS axis dominates, causing fluid retention even though BNP levels are markedly elevated.

Parameter	RAAS Effect	Natriuretic Peptide Effect
Renal Na⁺ handling	↑ Reabsorption (proximal tubule + collecting duct)	↑ Excretion (inhibits ENaC, dilates afferent arteriole)
Vascular tone	Vasoconstriction (↑ SVR)	Vasodilation (↓ SVR)
ADH secretion	Stimulated by Ang II	Inhibited by ANP
Sympathetic nervous system	Facilitated (central and peripheral)	Suppressed
Cardiac remodeling	Pro-hypertrophic and pro-fibrotic (AT₁)	Anti-hypertrophic (cGMP-mediated)

Opposing Actions of RAAS and Natriuretic Peptides

SECTION 6

Worked Example — Dehydration and RAAS Activation

Consider a 68-year-old male with chronic heart failure (NYHA Class III) who presents to the emergency department after three days of vomiting due to gastroenteritis. On examination, he is hypotensive (BP 88/52 mmHg), tachycardic (HR 112 bpm), and has decreased skin turgor. Labs show: serum Na⁺ 134 mEq/L, K⁺ 3.1 mEq/L, BUN 42 mg/dL, creatinine 1.8 mg/dL (baseline 1.2), and serum aldosterone elevated at 38 ng/dL. Let us trace the pathophysiology step by step.

Tracing RAAS Activation in a Dehydrated Heart Failure Patient

1
Step 1 — Identify the Volume Stimulus

Three days of vomiting produced significant gastrointestinal fluid losses (rich in Na⁺, K⁺, H⁺, and Cl⁻), reducing effective circulating volume. Although this patient already has impaired cardiac output from heart failure, superimposed dehydration further decreases ECV. The JGA senses reduced renal perfusion pressure (reflected in the hypotension) and decreased NaCl delivery to the macula densa.

All three renin-release triggers activated: ↓ afferent arteriolar pressure, ↓ macula densa NaCl, ↑ renal sympathetic activity.
2
Step 2 — Follow the Cascade

Renin cleaves hepatic angiotensinogen to angiotensin I. Pulmonary ACE converts angiotensin I to angiotensin II. Ang II acts on AT₁ receptors to produce systemic vasoconstriction (contributing to the residual diastolic pressure of 52 mmHg — without RAAS, it would likely be lower), stimulates aldosterone release from the adrenal cortex (serum aldosterone is 38 ng/dL, well above normal), and promotes ADH release from the posterior pituitary.

Elevated aldosterone (38 ng/dL) confirms maximal RAAS engagement.
3
Step 3 — Assess Renal Impact

The BUN-to-creatinine ratio is 42/1.8 ≈ 23:1, which exceeds the normal range (10–20:1) and suggests a prerenal azotemia pattern. Ang II constricts the efferent arteriole, attempting to preserve GFR. However, the fall in renal plasma flow is so great that GFR still declines, raising creatinine from 1.2 to 1.8 mg/dL. The elevated filtration fraction (due to efferent constriction) increases peritubular oncotic pressure, driving enhanced proximal tubular reabsorption of sodium, water, and urea — hence the disproportionate BUN elevation.

BUN:Cr ≈ 23:1 → prerenal pattern. Elevated FF drives proximal Na⁺/urea reabsorption.
4
Step 4 — Explain the Hypokalemia

Serum K⁺ is 3.1 mEq/L. Aldosterone stimulates ENaC-mediated Na⁺ reabsorption in the cortical collecting duct, generating a lumen-negative transepithelial voltage that drives K⁺ secretion through ROMK channels. Vomiting also contributes to potassium losses indirectly: gastric HCl loss produces metabolic alkalosis, which shifts K⁺ intracellularly and increases renal K⁺ excretion via bicarbonaturia-driven distal flow.

Hypokalemia (3.1 mEq/L) results from aldosterone-driven K⁺ secretion + alkalosis-mediated transcellular shift.
5
Step 5 — Therapeutic Implications

Initial management prioritizes volume resuscitation with isotonic crystalloid to restore ECV and suppress RAAS overdrive. As perfusion normalizes, renin release diminishes, aldosterone levels fall, renal function recovers (creatinine drifts toward baseline), and potassium begins to self-correct. The patient's chronic ACE inhibitor or ARB should be held during the acute hypovolemic phase because blocking RAAS during true volume depletion risks further hemodynamic compromise and acute kidney injury.

Volume resuscitation → ↓ renin → ↓ Ang II → ↓ aldosterone → corrects AKI and hypokalemia. Hold RAAS inhibitors in acute hypovolemia.

SECTION 7

Clinical Correlates — RAAS in Health vs. Disease

The clinical significance of RAAS becomes most apparent when one examines how the same cascade that preserves life during hemorrhage becomes a driver of morbidity in chronic disease. In decompensated heart failure, low cardiac output reduces renal perfusion and triggers RAAS despite elevated total body water. In cirrhosis, splanchnic vasodilation 'underfills' the arterial circulation, activating RAAS and producing avid sodium retention that manifests as ascites. In primary hyperaldosteronism, autonomous aldosterone secretion from an adrenal adenoma produces resistant hypertension with hypokalemia. The table below compares RAAS behavior across several important clinical scenarios.

Clinical Scenario	Renin Level	Aldosterone Level	ECV / Total Body Na⁺
Hemorrhage / Dehydration	↑↑ (appropriate)	↑↑	↓ ECV, ↓ Total body Na⁺
Heart Failure (decompensated)	↑↑ (maladaptive)	↑↑	↓ ECV, ↑ Total body Na⁺
Cirrhosis with Ascites	↑↑ (maladaptive)	↑↑	↓ ECV, ↑↑ Total body Na⁺
Primary Hyperaldosteronism	↓↓ (suppressed)	↑↑ (autonomous)	↑ ECV, ↑ Total body Na⁺
Renal Artery Stenosis	↑↑ (from ischemic kidney)	↑↑	↑ ECV (secondary hypertension)
Volume-Expanded / High-Na⁺ Diet	↓ (suppressed)	↓	↑ ECV, ↑ Total body Na⁺

RAAS Activation Across Clinical Scenarios

✦

KEY TAKEAWAY

The distinction between appropriate RAAS activation (hemorrhage, dehydration) and maladaptive RAAS activation (heart failure, cirrhosis) hinges on whether the ECV signal accurately reflects total body sodium status. In edematous states, the sensor (JGA) reads low ECV despite sodium-replete or sodium-overloaded interstitial compartments — like a fuel gauge that reads 'empty' because the fuel tank has a leak into an inaccessible compartment. This conceptual framework guides the use of RAAS-blocking drugs: they are life-saving in chronic maladaptive activation but potentially dangerous during genuine hypovolemia.

SECTION 8

Pharmacologic RAAS Blockade — From ACE Inhibitors to Novel Agents

The therapeutic interruption of RAAS at various points in the cascade represents one of the most impactful advances in cardiovascular and renal medicine. Each pharmacologic class targets a distinct enzymatic or receptor step, producing overlapping but not identical clinical effects. Understanding these differences informs rational drug selection and anticipation of adverse effects.

Drug Class	Target	Key Benefits	Notable Adverse Effects
ACE Inhibitors (e.g., enalapril)	ACE enzyme; blocks Ang I → Ang II conversion and bradykinin degradation	↓ BP, renoprotection, ↓ mortality in HF, ↓ post-MI remodeling	Dry cough (bradykinin), angioedema, hyperkalemia, teratogenicity
ARBs (e.g., losartan)	AT₁ receptor; selective blockade of Ang II signaling	Similar to ACEi; lower incidence of cough; ARB-preferred in ACEi-intolerant patients	Hyperkalemia, teratogenicity; avoid dual ACEi + ARB (↑ AKI risk)
MRAs (e.g., spironolactone, eplerenone)	Mineralocorticoid receptor in collecting duct and heart	↓ Mortality in HFrEF (RALES trial); anti-fibrotic; K⁺-sparing diuresis	Hyperkalemia, gynecomastia (spironolactone), requires K⁺ monitoring
Direct Renin Inhibitor (aliskiren)	Renin catalytic site; blocks angiotensinogen → Ang I	↓ BP; theoretical advantage of upstream blockade	Hyperkalemia, diarrhea; avoid with ACEi/ARB (ALTITUDE trial)
ARNI (sacubitril/valsartan)	Dual: neprilysin inhibitor (↑ natriuretic peptides) + ARB (↓ Ang II signaling)	Superior to ACEi in HFrEF (PARADIGM-HF); ↓ mortality, ↓ HF hospitalization	Hypotension, hyperkalemia, angioedema; 36-hour ACEi washout required

Pharmacologic Classes Targeting the RAAS Axis

The development of ARNIs (sacubitril/valsartan) represents a paradigm shift: rather than simply blocking the maladaptive RAAS arm, ARNIs simultaneously amplify the protective natriuretic peptide arm by inhibiting neprilysin, the enzyme that degrades ANP and BNP. The PARADIGM-HF trial demonstrated a 20% relative reduction in cardiovascular death or heart failure hospitalization compared with enalapril alone. Meanwhile, nonsteroidal MRAs such as finerenone offer more selective mineralocorticoid receptor antagonism with less hyperkalemia, and ongoing research continues to refine strategies for disrupting the RAAS–volume regulation axis in cardiorenal syndrome.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A patient with decompensated heart failure has peripheral edema, elevated jugular venous pressure, and pulmonary crackles — all signs of total body sodium and water excess. Paradoxically, plasma renin activity and aldosterone levels are markedly elevated. Explain why RAAS is activated despite apparent volume overload, referencing the concept of effective circulating volume.

Show answer

In decompensated heart failure, the failing ventricle delivers inadequate cardiac output, reducing arterial perfusion of the kidneys and other vital organs. The juxtaglomerular apparatus senses this reduced renal perfusion as 'low ECV,' even though total body sodium and water are clearly elevated (as evidenced by edema and JVD). The RAAS is activated because its sensors — the intrarenal baroreceptor, macula densa, and sympathetic nervous system — respond to the effective circulating volume (the blood that actually perfuses tissues), not total body water. This maladaptive RAAS activation drives further sodium and water retention, worsening congestion, creating a vicious cycle. This concept explains why RAAS inhibitors (ACEi, ARBs, MRAs, ARNIs) are cornerstone therapies in heart failure — they break this maladaptive cycle.

Question 2: BASIC CALCULATION

A patient's GFR is 110 mL/min and renal plasma flow (RPF) is 550 mL/min. After starting an ACE inhibitor, GFR decreases to 95 mL/min and RPF increases to 570 mL/min. Calculate the filtration fraction before and after ACE inhibitor initiation. Explain the physiological basis for the change.

Show answer

Filtration fraction (FF) = GFR / RPF. Before ACEi: FF = 110 / 550 = 0.20 (20%). After ACEi: FF = 95 / 570 ≈ 0.167 (16.7%). The filtration fraction decreased from 20% to approximately 16.7%. This occurs because ACE inhibitors block the conversion of angiotensin I to angiotensin II, reducing Ang II-mediated efferent arteriolar constriction. With less efferent tone, glomerular capillary hydrostatic pressure decreases (lowering GFR), while renal plasma flow increases due to reduced total renal vascular resistance. The net effect is a lower FF, which reduces peritubular capillary oncotic pressure and decreases proximal tubular sodium reabsorption — a renoprotective mechanism that lowers glomerular hypertension over the long term.

Question 3: INTERMEDIATE

A 55-year-old woman with resistant hypertension (BP 168/98 mmHg on three antihypertensives including a thiazide) is found to have a plasma aldosterone concentration (PAC) of 28 ng/dL and a plasma renin activity (PRA) of 0.3 ng/mL/hr. Calculate the aldosterone-to-renin ratio (ARR) and interpret the findings. What is the most likely diagnosis, and how does RAAS physiology explain the laboratory pattern?

Show answer

The ARR = PAC / PRA = 28 / 0.3 ≈ 93.3. An ARR greater than 30 (with PAC > 15 ng/dL) is considered a positive screening test for primary hyperaldosteronism. In this condition, an adrenal adenoma (or bilateral adrenal hyperplasia) autonomously secretes aldosterone independent of angiotensin II stimulation. The excessive aldosterone drives ENaC-mediated sodium reabsorption in the collecting duct, expanding extracellular volume, raising blood pressure, and promoting potassium secretion (often producing hypokalemia). The expanded volume increases renal perfusion pressure and NaCl delivery to the macula densa, which suppresses renin release through negative feedback — hence the very low PRA (0.3). The hallmark of primary hyperaldosteronism is therefore high aldosterone with suppressed renin, yielding a markedly elevated ARR. Confirmatory testing (e.g., saline infusion test) and adrenal CT/MRI would follow.

Question 4: APPLIED

A patient with stage 3 chronic kidney disease (baseline creatinine 2.0 mg/dL) is started on lisinopril for proteinuria reduction. Two weeks later, serum creatinine rises to 2.5 mg/dL and potassium is 5.6 mEq/L. The attending physician continues the medication. A third-year nursing student questions this decision. Using RAAS physiology, construct an argument supporting the attending's approach, and identify the point at which the drug should be discontinued.

Show answer

ACE inhibitors dilate the efferent arteriole by blocking Ang II production, reducing intraglomerular pressure and filtration fraction. This is the mechanism by which they slow CKD progression and reduce proteinuria. An initial rise in serum creatinine of up to 30% from baseline is an expected hemodynamic consequence of reduced glomerular hyperfiltration — it reflects reduced intraglomerular pressure, not parenchymal kidney injury. In this case, the creatinine rose from 2.0 to 2.5 mg/dL, a 25% increase, which falls within the acceptable range. The hyperkalemia (5.6 mEq/L) results from reduced aldosterone-mediated K⁺ secretion and reduced distal tubular flow. This is monitored closely. The drug should be discontinued or dose-reduced if creatinine rises more than 30% from baseline (i.e., above 2.6 mg/dL), if potassium exceeds 5.5–6.0 mEq/L despite dietary modification and possible addition of a potassium binder, or if the patient develops symptomatic hypotension or signs of acute kidney injury. The long-term renoprotective benefit of RAAS blockade generally outweighs the short-term creatinine rise in most CKD patients.

Question 5: CRITICAL THINKING

Sacubitril/valsartan (an ARNI) simultaneously inhibits neprilysin and blocks AT₁ receptors. Neprilysin degrades natriuretic peptides (ANP, BNP), bradykinin, and angiotensin II itself. Analyze why neprilysin inhibition alone (without concomitant AT₁ blockade) would be insufficient — or potentially harmful — as a heart failure therapy. In your answer, discuss the dual substrate problem and how the ARNI design resolves it.

Show answer

Neprilysin is a non-specific endopeptidase that degrades not only the beneficial natriuretic peptides (ANP, BNP) but also vasoactive peptides including bradykinin and — critically — angiotensin II. If neprilysin is inhibited in isolation, angiotensin II levels rise because one of its degradation pathways is blocked. This elevated Ang II would offset the vasodilatory and natriuretic benefits of elevated ANP/BNP, potentially causing net vasoconstriction, sodium retention, and worsening heart failure. This is the 'dual substrate problem': the enzyme targeted has both beneficial substrates (natriuretic peptides) and harmful substrates (Ang II) from the heart failure perspective. The ARNI design resolves this by coupling neprilysin inhibition (sacubitril) with AT₁ receptor blockade (valsartan). The ARB component blocks the downstream signaling of any accumulated Ang II, ensuring that the net hemodynamic effect is favorable — elevated natriuretic peptide activity dominates. This elegant pharmacologic strategy simultaneously amplifies the protective arm (natriuretic peptides) and suppresses the maladaptive arm (RAAS) of volume regulation. An ACE inhibitor cannot be substituted for the ARB component because both ACE and neprilysin degrade bradykinin; dual inhibition of both enzymes would dramatically elevate bradykinin levels, producing unacceptable rates of angioedema.

SUMMARY

Summary — RAAS & Volume Regulation Connections

Summary

The renin-angiotensin-aldosterone system is the body's principal hormonal cascade for defending effective circulating volume and mean arterial pressure. The cascade is initiated by the juxtaglomerular apparatus, which senses reduced renal perfusion, decreased tubular NaCl delivery, and increased sympathetic activity. Renin cleaves angiotensinogen to angiotensin I, which ACE converts to angiotensin II — the master effector that drives vasoconstriction, aldosterone-mediated sodium retention, and ADH-driven water reabsorption.

In health, negative feedback and the opposing natriuretic peptide system maintain ECV homeostasis. In disease states such as heart failure and cirrhosis, maladaptive RAAS activation perpetuates fluid retention and vascular remodeling. Pharmacologic interventions — ACE inhibitors, ARBs, MRAs, and ARNIs — target distinct points in the cascade and constitute the cornerstone of modern cardiorenal therapeutics. Mastery of RAAS physiology and its volume-regulation connections enables clinicians to predict drug effects, anticipate complications such as hyperkalemia and acute kidney injury, and tailor therapy to each patient's unique hemodynamic profile.